The efficacy and safety of crizotinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: a meta-analysis of clinical trials
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The efficacy and safety of crizotinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: a meta-analysis of clinical trials
Authors
Keywords
Meta-analysis, Crizotinib, Anaplastic lymphoma kinase (ALK), Non-small cell lung cancer (NSCLC)
Journal
BMC CANCER
Volume 14, Issue 1, Pages -
Publisher
Springer Nature
Online
2014-09-20
DOI
10.1186/1471-2407-14-683
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer
- (2014) Rajani Kanteti et al. BMC CANCER
- ALK-positive non-small cell lung cancer: Mechanisms of resistance and emerging treatment options
- (2014) Conor E. Steuer et al. CANCER
- Crizotinib: A New Treatment Option for ALK-Positive Non-Small Cell Lung Cancer
- (2013) Cindy L O'Bryant et al. ANNALS OF PHARMACOTHERAPY
- Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells
- (2013) Xi Chen et al. ANTI-CANCER DRUGS
- Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK-rearranged non–small–cell lung cancer harbored coexisting EGFRmutation
- (2013) Akihiko Miyanaga et al. BMC CANCER
- Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib
- (2013) Evelyn M. Brosnan et al. CANCER
- Clinical Benefit From Pemetrexed Before and After Crizotinib Exposure and From Crizotinib Before and After Pemetrexed Exposure in Patients With Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer
- (2013) Eamon M. Berge et al. Clinical Lung Cancer
- Crizotinib: A Review of Its Use in the Treatment of Anaplastic Lymphoma Kinase-Positive, Advanced Non-Small Cell Lung Cancer
- (2013) James E. Frampton DRUGS
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC
- (2013) Francesca Casaluce et al. Targeted Oncology
- Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
- (2012) D Ross Camidge et al. LANCET ONCOLOGY
- Crizotinib
- (2011) Monique P. Curran DRUGS
- Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
- (2011) Masahiro Fukuoka et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
- (2011) Alice T Shaw et al. LANCET ONCOLOGY
- Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged nonsmall cell lung cancer and beyond
- (2011) Sai-Hong Ignatius Ou Drug Design Development and Therapy
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now